Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 10/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.57 |
| ▸ | BCR | P11274 | 6/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945359 | 0.86 | ABL1 (0.70) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL2941616 | 0.86 | KIT (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941693 | 0.86 | ABL1 (0.67) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL30899721 | 0.86 | ABL1 (0.67) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL1408815 | 0.86 | ABL1 (0.77) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL3247337 | 0.85 | PIKFYVE (0.65) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL2940451 | 0.85 | ABL1 (0.59) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL2946486 | 0.84 | ABL1 (0.59) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2939269 | 0.83 | ABL1 (0.61) | PIKFYVEABL1PDGFRABCRPDGFRB | |
| SCHEMBL1415439 | 0.83 | ABL1 (0.74) | PIKFYVEABL1PDGFRABCRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101218241-B | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC | 2011-02-16 | — | — | CN | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| CN-101218241-A | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC (BM) | 2008-07-09 | — | — | CN | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| CN-101218241-B | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC | 2011-02-16 | — | — | CN | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| CN-101218241-A | Pyrrolopyridine derivatives as protein kinase inhibitors | IRM LLC (BM) | 2008-07-09 | — | — | CN | disclosed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | PIKFYVE 157/4885ABL1 13/4885PDGFRA 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.